Literature DB >> 27529458

Mixed acute kidney allograft rejection after an antiprogrammed cell death protein 1 antibody treatment for lung epidermoid carcinoma.

Mathilde Tamain1,2, Cyril Garrouste3, Didier Aguilera4, Aurélien Tiple3, Souad Salhi5, George Kosmadakis4, Anne-Elisabeth Heng3,6.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27529458     DOI: 10.1111/tri.12834

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


× No keyword cloud information.
  5 in total

1.  Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue.

Authors:  Luis E Aguirre; Maria E Guzman; Gilberto Lopes; Judith Hurley
Journal:  Oncologist       Date:  2018-11-09

2.  The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.

Authors:  Vivek Kumar; Atul B Shinagare; Helmut G Rennke; Sandeep Ghai; Jochen H Lorch; Patrick A Ott; Osama E Rahma
Journal:  Oncologist       Date:  2020-02-11

3.  Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients.

Authors:  Sandhya Manohar; Charat Thongprayoon; Wisit Cheungpasitporn; Svetomir N Markovic; Sandra M Herrmann
Journal:  Kidney Int Rep       Date:  2019-12-07

Review 4.  The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?

Authors:  Rossana Franzin; Giuseppe Stefano Netti; Federica Spadaccino; Camillo Porta; Loreto Gesualdo; Giovanni Stallone; Giuseppe Castellano; Elena Ranieri
Journal:  Front Immunol       Date:  2020-10-08       Impact factor: 7.561

Review 5.  Programmed Cell Death 1 (PD-1) Inhibitors in Renal Transplant Patients with Advanced Cancer: A Double-Edged Sword?

Authors:  Hung-Chih Lai; Ji-Fan Lin; Thomas I S Hwang; Ya-Fang Liu; An-Hang Yang; Chung-Kuan Wu
Journal:  Int J Mol Sci       Date:  2019-05-03       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.